Bio

Simon Elliott is a senior managing director in Evercore’s healthcare corporate advisory business based in London. He has worked extensively with clients across the healthcare subsectors, including pharma, biotech, medtech and healthcare services. Recent notable transactions include advising AstraZeneca on its acquisition of Alexion; Philips on its acquisitions of BioTelemetry and Capsule Technologies; Sanofi on its acquisition of Principia Biopharma; Novo Nordisk on its acquisition of Emisphere Technologies; Eli Lilly on its acquisition of Dermira (and subsequent sale of Qbrexza); Bristol-Myers Squibb on its acquisition of Celgene; AstraZeneca on the c. $1.6bn sale of its anti-infections business to Pfizer; AstraZeneca on its defense against Pfizer; Shire on its acquisition of Baxalta International for $32bn; Takeda Pharmaceutical on its c. $62bn acquisition of Shire and subsequent sale of Xiidra to Novartis; Takeda on its $5.2bn acquisition of Ariad Pharmaceuticals; and Partners Group and Duke Street on the acquisition of Voyage Care. Prior to joining Evercore, Mr Elliott worked at Deutsche Bank, where he advised a number of European healthcare clients, including Smith and Nephew on its acquisition of Healthpoint Biotherapeutics; GlaxoSmithKline on the sale of its stake in Quest Diagnostics; Grifols on the acquisition of Talecris Biotherapeutics Holdings; Shire on its acquisition of Movetis; Advent International on the acquisition of The Priory Group; EQT on the acquisition of BSN medical; and Lundbeck on the acquisition of Ovation Pharmaceuticals. Mr. Elliott also previously worked at Lehman Brothers in the European healthcare corporate finance team and was particularly focused on the biotech and pharma space; select deals included the sale of Fumapharm to Biogen Idec, the sale of PowderMed to Pfizer, the sale of Domantis to GlaxoSmithKline and the sale of Dako Denmark to EQT. He began his career as an equity research analyst at Lehman Brothers covering the European life sciences sector. Mr. Elliott received a master’s in biochemistry from the University of Oxford.